Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r.sup.2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.

The present disclosure relates to methods for determining a viral titer of a biological sample, suitably from a mammalian cell sample. The methods include the use of mechanical disruption of the cells, followed by droplet digital polymerase chain reaction (ddPCR) to determine the viral titer. Methods of mechanical disruption suitably include the use of glass beads.

The present invention provides methods of diagnosing and treating fast aging skin, especially in young subjects, by measuring and/or adjusting a property selected from cell proliferation rate, NFKB1 gene expression, CDKN1A gene expression, CDKN2A gene expression, CEBPB gene expression, and combinations thereof.

Compositions and methods for identifying and using cis-regulatory and decoy sequences are disclosed.

The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.

The present disclosure relates to the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and diseases related to vascular ageing and in the treatment of smooth muscle cells diseases, in particular an inhibitor of a metalloprotease the treatment of smooth muscle cells diseases. The disclosure subject matter describes a more effective therapies for the treatment of Hutchinson-Gilford Progeria Syndrome and diseases related to vascular ageing, or namely by the use of an inhibitor of a metalloprotease.

The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.